Indian stocks: Visit www.stage2stocks.com →

NervGen Pharma Corp.

Stage 1 · Basing · week 7

As of Oct 22, 2026, NervGen Pharma is in Stage 1, the basing phase, now in week 7 (since Sep 4, 2026). It closed at $1.42, 76.2% below its 52-week high and below its 200-day average, which is falling.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More about the company

$1.42
-5.51% today
$153M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is NGEN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 14w
S2 14w
S2 21w
S4 13w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 10w → S3 7w → S2 14w → S3 6w → S4 6w → S1 3w → S2 10w → S3 4w → S4 8w → S1 1w → S2 12w → S3 5w → S2 14w → S3 10w → S2 21w → S3 13w → S4 13w → S1 7w current
Total tracked: 165 weeks across 19 stage runs.

NGEN among Biotechnology357th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…357NGENStage 1 · wk 723−27.6%
vs 52W High
-76.2%
$1.42 lo$5.97 hi
76.2% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 7
1w13w26w
Week 7, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-52.2%
200 DMA: $2.97 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.18x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-27.6%
3M
-12.9%
6M
-63.9%
YTD
-75.9%
1Y
-51.5%
Scan Membership
Breakout Watch
Latest: 2025-04-23
10 appearances in last 60 days. First seen: 2020-01-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 7 · Vol 1.18x
2026-10-21S1
Wk 7 · Vol 0.53x
2026-10-20S1
Wk 7 · Vol 0.43x
2026-10-19S1
Wk 7 · Vol 0.80x
2026-10-16S1
Wk 6 · Vol 0.73x
2026-10-15S1
Wk 6 · Vol 0.89x
2026-10-14S1
Wk 6 · Vol 2.52x
2026-10-13S1
Wk 6 · Vol 0.99x
2026-10-12S1
Wk 6 · Vol 0.43x
2026-10-09S1
Wk 5 · Vol 0.58x
2026-10-08S1
Wk 5 · Vol 0.57x
2026-10-07S1
Wk 5 · Vol 0.45x
Moving averages & range
50 DMA
$1.93
200 DMA
$2.97
52W High
$5.97
52W Low
$1.42
5D Low
$1.42
Resistance levels (recent highs)
20d High
$1.94
60d High
$2.34
120d High
$3.89
250d High
$5.97
Next resistance
+36.6%
to 20d High
ROE
-96.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 4.5

NervGen Pharma: quick answers

What stage is NervGen Pharma in?

As of Oct 22, 2026, NervGen Pharma (NGEN) is in Stage 1, the basing phase. It entered Stage 1 on Sep 4, 2026 and is in week 7. What the four stages mean

Is NervGen Pharma in an uptrend?

Not yet. NervGen Pharma is in Stage 1, a base that can come before an uptrend. It trades 52.2% below its 200-day average, which is falling.

How far is NervGen Pharma from its 52-week high?

NervGen Pharma closed at $1.42 on Oct 22, 2026, 76.2% below its 52-week high of $5.97. Its 52-week low is $1.42.

How has NervGen Pharma performed over the past year?

As of Oct 22, 2026, NervGen Pharma is down 51.5% over the past year and down 75.9% so far in 2026.

Which sector and industry is NervGen Pharma in?

NervGen Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.